Mutual of America Capital Management LLC Trims Holdings in Abbott Laboratories (NYSE:ABT)

Mutual of America Capital Management LLC reduced its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 213,963 shares of the healthcare product maker's stock after selling 5,164 shares during the period. Mutual of America Capital Management LLC's holdings in Abbott Laboratories were worth $24,394,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Accredited Investors Inc. increased its position in shares of Abbott Laboratories by 8.3% during the third quarter. Accredited Investors Inc. now owns 13,788 shares of the healthcare product maker's stock valued at $1,572,000 after acquiring an additional 1,062 shares in the last quarter. River Street Advisors LLC boosted its position in Abbott Laboratories by 16.4% in the 3rd quarter. River Street Advisors LLC now owns 7,282 shares of the healthcare product maker's stock valued at $830,000 after buying an additional 1,025 shares during the period. Turtle Creek Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 5.1% in the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 4,735 shares of the healthcare product maker's stock worth $540,000 after purchasing an additional 229 shares during the period. KPP Advisory Services LLC lifted its position in shares of Abbott Laboratories by 5.1% in the 3rd quarter. KPP Advisory Services LLC now owns 8,387 shares of the healthcare product maker's stock worth $956,000 after purchasing an additional 405 shares during the period. Finally, Natixis Advisors LLC lifted its position in Abbott Laboratories by 16.8% during the third quarter. Natixis Advisors LLC now owns 1,423,015 shares of the healthcare product maker's stock valued at $162,238,000 after acquiring an additional 204,478 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In related news, CEO Robert B. Ford sold 141,679 shares of the business's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. The trade was a 39.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.10% of the stock is currently owned by corporate insiders.

Abbott Laboratories Stock Up 0.8 %

Shares of ABT stock traded up $0.87 during trading on Friday, reaching $115.90. The company's stock had a trading volume of 6,898,605 shares, compared to its average volume of 5,386,244. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The company has a market capitalization of $201.02 billion, a price-to-earnings ratio of 35.23, a P/E/G ratio of 2.73 and a beta of 0.72. The stock's 50-day moving average price is $115.53 and its 200 day moving average price is $109.52. Abbott Laboratories has a 1-year low of $97.64 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, beating analysts' consensus estimates of $1.20 by $0.01. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $10.55 billion. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The business's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. On average, research analysts anticipate that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th were issued a $0.55 dividend. The ex-dividend date was Tuesday, October 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.90%. Abbott Laboratories's payout ratio is 66.87%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ABT shares. Jefferies Financial Group upped their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company a "hold" rating in a research note on Thursday, October 17th. UBS Group increased their price objective on shares of Abbott Laboratories from $143.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. Edward Jones lowered shares of Abbott Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, July 30th. Oppenheimer initiated coverage on shares of Abbott Laboratories in a report on Tuesday, October 8th. They set an "outperform" rating and a $130.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an "equal weight" rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $130.07.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.